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Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) is a tyrosine kinase receptor, expressed primarily in 
endothelial cells, and is activated by the specific binding of VEGF, produced and released by the tumor, to the 
VEGFR2 extracellular regulatory domain, undergoing autophosphorylation, triggering signaling pathways 
leading to endothelial cell proliferation towards the tumor [!].Small molecules may act as inhibitors by 
competing for the ATP-binding site of the VEGFR2 intracellular tyrosine kinase domain, thereby preventing the 
intracellular signaling that leads to angiogenesis [2]. Herein, we report the synthesis using rational design of new 
1-aryl-3-[3-thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas (la-c) as VEGFR2 tyrosine kinase inhibitors. The 
compounds presented, with the arylurea in the meta position to the thioether and with F or a Me group, showed 
very low !Cso values (11-28 nM) in enzymatic assays as predicted by molecular docking. 
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To examine the activity of compounds 1 in endothelial cells, VEGF-stimulated (60 ng/mL) Human Umbilical 
Vein Endothelial Cells (HUVECs) were cultured in M199 medium in the absence (C) or presence of each 
compound at different concentrations. A remarkable reduction in the proliferation of HUVECs using the BrdU 
incorporation assay was observed for all compounds at I !JM, for compound la being observed a higher 
antiproliferative effect. Further studies are ongoing to examine whether these molecules affect the expression 
and activity of VEGFR2 and the signaling pathways, using western blotting assays. Given the established role of 
VEGFR2 in proliferation and migration of endothelial cells, these molecules are promising anti-angiogenic 
agents that can be used for therapeutic purposes in pathological conditions where angiogenesis is exacerbated, 
such as cancer. 
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